Sugi Predict

Sugi Predict / Compounds / SCHEMBL871327

SCHEMBL871327

SCHEMBL871327

O=Cc1cn2ccccc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 1/20 0.51
▸ PTGS2 P35354 1/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ LMNA P02545 2/20 0.49
▸ HDAC1 Q13547 1/20 0.48
▸ HDAC2 Q92769 1/20 0.48
▸ MAPT P10636 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ RAB9A P51151 10/20 0.45
▸ NPC1 O15118 9/20 0.45
▸ KDM4E B2RXH2 7/20 0.45
▸ POLB P06746 1/20 0.45
▸ GFER P55789 2/20 0.44
▸ ALOX12 P18054 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27899681 0.81 PTGS1 (0.47) PTGS1PTGS2SMN1; SMN2ALDH1A1HDAC1
SCHEMBL10542566 0.79 PTGS1 (0.46) PTGS1PTGS2SMN1; SMN2ALDH1A1LMNA
SCHEMBL18851551 0.78 HDAC1 (0.49) PTGS1PTGS2SMN1; SMN2ALDH1A1HDAC1
SCHEMBL19456997 0.77 PTGS1 (0.47) PTGS1PTGS2SMN1; SMN2ALDH1A1HDAC1
SCHEMBL9605459 0.77 HDAC1 (0.48) PTGS1PTGS2SMN1; SMN2ALDH1A1LMNA
SCHEMBL5773449 0.76 APP (0.43) SMN1; SMN2ALDH1A1LMNAHDAC1HDAC2
SCHEMBL11914803 0.75 ALDH1A3 (0.60) SMN1; SMN2ALDH1A1RAB9ANPC1KDM4E
SCHEMBL871995 0.73 NPC1 (0.50) SMN1; SMN2ALDH1A1LMNAMAPTRAB9A
SCHEMBL24158896 0.73 SMN1; SMN2 (0.56) PTGS1PTGS2SMN1; SMN2ALDH1A1LMNA
SCHEMBL4885799 0.73 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1MAPTCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3364967-B1 FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2026-05-20 — — EP disclosed
US-12473303-B2 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use Carrick Therapeutics Limited (IE) 2025-11-18 — — US disclosed
US-20250262201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2025-08-21 — — US disclosed
EP-4549440-A1 CLASS OF PRMT5 INHIBITORS AND USE THEREOF Cytosinlab Therapeutics Co., Ltd. (CN) 2025-05-07 — — EP disclosed
CN-119775261-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2025-04-08 — — CN disclosed
CN-119562954-A PRMT5 inhibitor and application thereof 上海赛岚生物科技有限公司 2025-03-04 — — CN disclosed
CN-114929708-B 4- [ [ (7-Aminopyrazolo [1,5-a ] pyrimidin-5-yl) amino ] methyl ] piperidin-3-ol compounds and their therapeutic uses 卡里克治疗有限公司 2025-02-18 — — CN disclosed
CN-115427404-B Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2024-12-13 — — CN disclosed
US-20240376126-A1 PRMT5 INHIBITOR AND THE USE THEREOF CYTOSINLAB THERAPEUTICS CO., LTD. (CN) 2024-11-14 — — US disclosed
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 — — US disclosed
WO-2004074270-A2 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2004-09-02 — — WO disclosed
US-6521621-B1 Tachykinin antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2003-02-18 — — US disclosed
US-6197772-B1 TACHYKININS ANTAGONIST; ANTIINFLAMMATION AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2001-03-06 — — US disclosed
EP-0862566-B1 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2000-01-12 — — EP disclosed
EP-0862566-A1 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1998-09-09 — — EP disclosed
WO-1997016440-A1 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1997-05-09 — — WO disclosed
US-5063229-A Antiinflammatory agents ROUSSEL ULCAF (FR) 1991-11-05 — — US disclosed
US-4895866-A Anti-inflammatory imidazole compounds ROUSSEL UCLAF (FR) 1990-01-23 — — US disclosed
US-4810828-A ANTIARTHRITIC, PSORIASIS ROUSSEL UCLAF (FR) 1989-03-07 — — US disclosed
US-4450164-A ANTIULCER AND ANTISECRETORY AGENTS SCHERING CORPORATION (US) 1984-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250262201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 PTGS1 2084/4885PTGS2 3099/4885SMN1; SMN2 1592/4885
US-20240376126-A1 PRMT5 INHIBITOR AND THE USE THEREOF PRMT5, PRMT1, PRMT6 PTGS1 3938/4885PTGS2 4266/4885SMN1; SMN2 968/4885
US-12473303-B2 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use CDK3, CDK1, CDK2 PTGS1 2933/4885PTGS2 2391/4885SMN1; SMN2 953/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 PTGS1 1502/4885PTGS2 2218/4885SMN1; SMN2 2456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.